Back to Authors

Rostásy, Kevin

https://orcid.org/0000-0002-2180-5321

Mayo Clinic

Vestische Caritas-Kliniken

Citations 3

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations
Hua, Le H. , Solomon, Andrew , Tenembaum, Sílvia , Rostásy, Kevin , Newsome, Scott D. , Marrie, Ruth Ann , Magyari, Melinda , Kantarci, Orhun H. , Cohen, Jeffrey A., Bove, Riley , Banwell, Brenda , Magyari, Melinda , Scalfari, Antonio , Rovira, Àlex , Hemmer, Bernhard , Hemingway, Cheryl , Harnegie, Mary Pat , Graves, Jennifer , Corboy, John R. , Waubant, Emmanuelle L.

JAMA Neurology | September 16, 2024 | Volume: 81 | Issue: 11 | Pages: 1210

10.1001/jamaneurol.2024.3062 Get It

Importance While the typical onset of multiple sclerosis (MS) occurs in early adulthood, 2% to 10% of cases initially present prior to age 18 years, and approximately 5% after age 50 years. Guidance on approaches to differential diagnosis in suspected MS specific to these 2 age groups is needed. Observations There are unique biological factors in children younger than 18 years and in adults older than age 50 years compared to typical adult-onset MS. These biological differences, particularly immunological and hormonal, may influence the clinical presentation of MS, resilience to neuronal injury, and differential diagnosis. While mimics of MS at the typical age at onset have been described, a comprehensive approach focused on the younger and older ends of the age spectrum has not been previously published. Conclusions and Relevance An international committee of MS experts in pediatric and adult MS was formed to provide consensus guidance on diagnostic approaches and key clinical and paraclinical red flags for non-MS diagnosis in children and older adults.
Novel congenital disorder of O -linked glycosylation caused by GALNT2 loss of function
Zilmer, Monica , Edmondson, Andrew C. , Khetarpal, Sumeet A. , Alesi, Viola , Zaki, Maha S. , Rostásy, Kevin , Madsen, Charlotte , Lepri, Francesca Romana , Sinibaldi, Lorenzo , Novelli, Antonio , Issa, Mahmoud Y. , Fenger, Christina , Agolini, Emanuele , Petäjä‐Repo, Ulla E. , Hintze, John , Raymond, Kimiyo , Liedtke, Kristen, Stanley, Valentina , Musaev, Damir, Gleeson, Joseph G. , Vitali, Cecilia , Rubboli, Guido , Schjoldager, Katrine T. , Møller, Rikke S. , Raymond, Kimiyo M, Agolini, Emanuele , Rubboli, Guido , Edmondson, Andrew C , Møller, Rikke S , Madsen, Camilla G, Cusmai, Raffaella , Jamra, Rami Abou , Reutter, Heiko , Briuglia, Silvana , Hansen, Lars Hestbjerg , Stanley, Valentina , Gleeson, Joseph G. , O’Brien, W Timothy, Gardella, Elena , Rader, Daniel J

Brain | February 17, 2020 | Volume: 143 | Issue: 4 | Pages: 1114-1126

10.1093/brain/awaa063 Get It

Abstract Congenital disorders of glycosylation are a growing group of rare genetic disorders caused by deficient protein and lipid glycosylation. Here, we report the clinical, biochemical, and molecular features of seven patients from four families with GALNT2-congenital disorder of glycosylation (GALNT2-CDG), an O-linked glycosylation disorder. GALNT2 encodes the Golgi-localized polypeptide N-acetyl-d-galactosamine-transferase 2 isoenzyme. GALNT2 is widely expressed in most cell types and directs initiation of mucin-type protein O-glycosylation. All patients showed loss of O-glycosylation of apolipoprotein C-III, a non-redundant substrate for GALNT2. Patients with GALNT2-CDG generally exhibit a syndrome characterized by global developmental delay, intellectual disability with language deficit, autistic features, behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic features, decreased stature, and decreased high density lipoprotein cholesterol levels. Rodent (mouse and rat) models of GALNT2-CDG recapitulated much of the human phenotype, including poor growth and neurodevelopmental abnormalities. In behavioural studies, GALNT2-CDG mice demonstrated cerebellar motor deficits, decreased sociability, and impaired sensory integration and processing. The multisystem nature of phenotypes in patients and rodent models of GALNT2-CDG suggest that there are multiple non-redundant protein substrates of GALNT2 in various tissues, including brain, which are critical to normal growth and development.